Pharma News

The Union Ministry of Health and Family Welfare has released a draft notification proposing a distinct blue vertical line on the labels of all antimicrobial medicines, a move aimed at improving identification and promoting the rational use of antibiotics in the country.

In a move aimed at accelerating drug development while maintaining regulatory oversight, India’s drug regulator has notified sweeping changes to the New Drugs and Clinical Trials (NDCT) Rules, 2019, introducing a faster “prior intimation” route for select test licences and sharply reducing approval timelines.

The amendments, notified on January 20, 2026, under G.S.R. 46(E), mark a significant shift in how manufacturers can produce new drugs and investigational products for clinical trials, bioavailability, bioequivalence studies, and analytical testing

The proposed India-European Union (EU) trade deal is expected to bring significant benefits to India’s pharmaceutical industry. The EU is one of the largest and most regulated medicine markets in the world, and easier access to this region can open new growth opportunities for Indian drug manufacturers. The agreement focuses not only on trade but also on regulatory cooperation, which is crucial for pharmaceuticals.

An international team of researchers has uncovered a crucial mechanism that allows certain cancer cells to hide from the body’s immune defenses, a discovery that could reshape future cancer treatments. The study, led by scientists at Julius-Maximilians-Universität Würzburg (JMU) in collaboration with partners in the United States, reveals how the powerful cancer-driving protein MYC not only fuels tumor growth but also helps tumors remain undetected by the immune system.

A new epidemiological study reported today finds that consistent heavy alcohol consumption over a lifetime is associated with a significantly increased risk of colorectal cancer, particularly rectal cancer, while reducing or quitting drinking may lower that risk. The findings were published online in the peer-reviewed journal Cancer.

Syngene announced a significant extension of its long-standing collaboration with global biopharmaceutical leader Bristol Myers Squibb (BMS). The renewed strategic agreement will now continue through 2035, marking a new decade of deep partnership aimed at driving drug discovery, development, and commercialization.